Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning

Sponsor
Ain Shams University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04807634
Collaborator
(none)
30
1
2
5.7
5.2

Study Details

Study Description

Brief Summary

Intravenous Lipid Emulsion in Improving Coma Of Antipsychotic drugs Acute Poisoning: A Randomized Controlled Trial in Poison Control Center of Ain Shams University Hospitals

Condition or Disease Intervention/Treatment Phase
  • Drug: Intravenous Lipid Emulsion (Intralipid 20%)
N/A

Detailed Description

Intravenous lipid emulsions (ILEs) have been recently used in treatment of acute toxicity caused by lipophilic drugs including local anesthetics, antidepressants, anti-arrhythmics, beta blockers and calcium channel antagonists with few case reports concerning their use in treatment of acute antipsychotics overdose (Muller et al., 2015).

To the best of our knowledge, no randomized controlled trials (RCTs) have been performed to evaluate the antidotal effect of ILEs on the level of consciousness of acutely poisoned patients by antipsychotics and their routine metabolic profile tests.

Acute poisoning by antipsychotics could result in various life-threatening toxic effects mainly on cardiovascular and central nervous systems (CNS). Tachycardia, hypotension, and QT prolongation in electrocardiogram are the most common cardiovascular findings while sedation, extrapyramidal symptoms, agitation, and coma are the most common CNS findings following acute antipsychotic exposures (Divac et al., 2014).

As acute antipsychotic drugs overdose lack specific antidote, the primary goal in treatment is aggressive supportive therapy. In order to prevent CNS depression and respiratory failure, patients may need to be supported by mechanical ventilation. Hypotension is treated by intravenous fluids with use of direct-acting vasopressors (Orazel et al., 2019).

Several mechanisms for the antidotal properties of ILEs have been proposed including their ability to capture lipophilic drugs and extract them from vital organs such as the heart and brain thus reducing their toxicity, preferential distribution of lipophilic drugs into a circulating lipid phase, thereby reducing tissue drug concentrations. In addition, ILEs have direct inotropic effect due to improved fatty acid oxidative metabolism resulting in restoration of myocardial contractility (Zyoud et al., 2016 & Kehayova et al., 2019).

Sample size:

• Based on the calculated sample size by statistics committee (Community Medicine, Environmental, and Occupational Medicine Department - Faculty of Medicine, Ain shams University), a total of at least 30 patients with history of acute intoxication by antipsychotic drugs will be enrolled and randomly assigned into case (n=15) and control (n=15) groups.

Method of rondamization:

• Randomization will be achieved via a computer-generated random -sequence table.

On admission, the patient will receive the conventional management including history taking, clinical examination, investigations and treatment .

Examination will be repeated every six hours through the period of hospital stay of the patient.

All clinical data of the patient will be recorded in a special sheet that include the following data :

  1. Sociodemographic data:
  • Age.

  • Gender.

  • Residence

  1. Intoxication data:
  • Type of antipsychotic drug responsible for intoxication.

  • Amount of antipsychotic drug (if available).

  • Mode of poisoning, whether suicidal, accidental, criminal or therapeutic error.

  • Route of intake of the poison.

  • Time elapsed between the exposure and arrival to the PCC-ASU (delay time).

  • Preconsultation management.

  • Presence of comorbidities (as underlying medical or psychiatric diseases).

  • The current medications used by the patient including all drugs used in treatment of diseases.

  1. Clinical data (on admission and during hospital stay):
  • In both groups, detailed examination of the patients will be carried out on admission and routinely according to the severity of poisoning.

  • Assessment of the level of consciousness of all patients under the study will be carried out on admission and every six hours by using Glasgow coma scale (GCS) and Alert, Voice, Pain, Unresponsive (AVPU) scale till the patient discharge or mortality.

  1. Investigations:
  • Laboratory: all required laboratory investigations will be performed including arterial blood gas (ABG) analysis, and routine metabolic profile tests (e.g. glucose, sodium, potassium, urea and creatinine).

  • Other required investigations: Electrocardigraphy (ECG) will be done on admission and 12 h later, then every 24 h till the patient discharge or mortality.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trial (RCT).Randomized controlled trial (RCT).
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning: A Randomized Controlled Trial in PoisonControl Center of Ain Shams University Hospitals
Actual Study Start Date :
Mar 10, 2021
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Sep 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Other: Group A (control)

Group A (control): that will receive the traditional supportive treatment for acute antipsychotic drugs overdose

Drug: Intravenous Lipid Emulsion (Intralipid 20%)
Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
Other Names:
  • Intralipid 20%
  • Other: Group B (case)

    that will receive the traditional supportive treatment for acute antipsychotic drugs overdose plus administration of 1.5 ml/kg ILE (20%) as a bolus over 1-2 minutes, followed by a continuous rate infusion of 0.25 ml/kg/min for the next 30 to 60 minutes

    Drug: Intravenous Lipid Emulsion (Intralipid 20%)
    Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
    Other Names:
  • Intralipid 20%
  • Outcome Measures

    Primary Outcome Measures

    1. Complete recovery [6 months]

      Regaining consciousness with galasco coma scale 15/15 without presence of other clinical manifestations denoting antipsychotics toxicity.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All adult comatose patients admitted to the ICU of Poison Control Center of Ain Shams University Hospitals with positive history of antisychotic drugs overdose during the period starting from the beginning of March 2020 to the end of Septemper 2021
    Exclusion Criteria:
    • Based on the possibility of heterogeneity in hemodynamic parameters, laboratory variables, GCS and/or AVPU Scale, the following patients will be excluded:

    • Patients less than 18 years and more than 65 years.

    • Pregnant and lactating females.

    • Co-ingestion of other agents.

    • Presence of medical diseases (e.g. renal, hepatic, cardiovascular diseases) and chronic pancreatitis.

    • History of head trauma.

    • Presence of conditions where ILE is contraindicated.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hend salama shalby El Far Cairo Egypt

    Sponsors and Collaborators

    • Ain Shams University

    Investigators

    • Study Chair: Manal A Abdel Salam, Professor, Ain Shams University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT04807634
    Other Study ID Numbers:
    • AinShamsU RCT
    First Posted:
    Mar 19, 2021
    Last Update Posted:
    Mar 19, 2021
    Last Verified:
    Mar 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Ain Shams University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 19, 2021